Dimer Pharmaceuticals
Biotechnology company developing therapeutics that leverage shared biology between cancer and neurodegeneration. The organization focuses on targeting MYCN gene amplification and protein homeostasis pathways—using small-molecule approaches and a translational platform—to address aggressive pediatric neural tumors and MYC-N driven adult cancers. Leadership describes experience in translational development, regulatory submissions, adaptive clinical trial design, and partnership formation.
Industries
N/A
Products
Small-molecule therapeutic targeting MYC-N-driven cancers (pilot program)
Pilot therapeutic program from a platform designed to disrupt MYC-N-driven pathways using a novel small-molecule approach, initially focused on pediatric high-risk neural tumors and intended to scale to other MYC-N overexpressing cancers and related neurodegenerative indications.
Small-molecule therapeutic targeting MYC-N-driven cancers (pilot program)
Pilot therapeutic program from a platform designed to disrupt MYC-N-driven pathways using a novel small-molecule approach, initially focused on pediatric high-risk neural tumors and intended to scale to other MYC-N overexpressing cancers and related neurodegenerative indications.
Expertise Areas
- Targeted oncology drug development
- Prion biology and protein homeostasis
- Translational research (oncology and neurodegeneration)
- Small-molecule therapeutic development
Key Technologies
- Small-molecule therapeutics
- Targeting MYCN (oncogene-directed therapy)
- Prion biology and protein homeostasis modulation
- Translational therapeutic platform